IBDEI3BX ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.4,2293,0)
;;=RETINA - VASCULAR^12^176
;;^UTILITY(U,$J,358.4,2294,0)
;;=EYELIDS / LASHES^2^176
;;^UTILITY(U,$J,358.4,2295,0)
;;=NEURO / STRABISMUS^18^176
;;^UTILITY(U,$J,358.4,2296,0)
;;=ORBIT - PLASTICS^20^176
;;^UTILITY(U,$J,358.4,2297,0)
;;=VITREOUS^17^176
;;^UTILITY(U,$J,358.4,2298,0)
;;=ORBIT - TRAUMA^19^176
;;^UTILITY(U,$J,358.4,2299,0)
;;=LACRIMAL / NLD / NEOPLASMS^3^176
;;^UTILITY(U,$J,358.4,2300,0)
;;=MOST FREQUENT^1^176
;;^UTILITY(U,$J,358.4,2301,0)
;;=CONJUNCTIVA / SCLERA^4^176
;;^UTILITY(U,$J,358.4,2302,0)
;;=CORNEA / ULCER^5^176
;;^UTILITY(U,$J,358.4,2303,0)
;;=LENS / CATARACT / POSTOP^6^176
;;^UTILITY(U,$J,358.4,2304,0)
;;=IRIS / UVEITIS^7^176
;;^UTILITY(U,$J,358.4,2305,0)
;;=GLAUCOMA - OPEN ANGLE^8^176
;;^UTILITY(U,$J,358.4,2306,0)
;;=GLAUCOMA - CLOSED ANGLE^9^176
;;^UTILITY(U,$J,358.4,2307,0)
;;=GLAUCOMA - SECONDARY^10^176
;;^UTILITY(U,$J,358.4,2308,0)
;;=RETINA - CHOROID / TUMORS / INFLAM^14^176
;;^UTILITY(U,$J,358.4,2309,0)
;;=RETINA - TEAR / PERIPH / DEGENERATION^15^176
;;^UTILITY(U,$J,358.4,2310,0)
;;=RETINA - MACULA^11^176
;;^UTILITY(U,$J,358.4,2311,0)
;;=SUICIDE IDEATIONS/ATTEMPTS^23^176
;;^UTILITY(U,$J,358.4,2312,0)
;;=PMH / OTHER^22^176
;;^UTILITY(U,$J,358.4,2313,0)
;;=RETINA - VEGF INJECT DX CODES^16^176
;;^UTILITY(U,$J,358.4,2314,0)
;;=RETINA - DIABETIC RETINOPATHY^13^176
;;^UTILITY(U,$J,358.4,2315,0)
;;=NEW PATIENT^2^177
;;^UTILITY(U,$J,358.4,2316,0)
;;=ESTABLISHED PATIENT^1^177
;;^UTILITY(U,$J,358.4,2317,0)
;;=CONSULTATIONS^3^177
;;^UTILITY(U,$J,358.4,2318,0)
;;=POST OP VISIT (GLOBAL)^4^177
;;^UTILITY(U,$J,358.4,2319,0)
;;=PENIS & SCROTUM^7^178
;;^UTILITY(U,$J,358.4,2320,0)
;;=URINARY TRACT DRAINAGE & IMAGING^9^178
;;^UTILITY(U,$J,358.4,2321,0)
;;=URODYNAMICS^10^178
;;^UTILITY(U,$J,358.4,2322,0)
;;=INJ & INTRAVESICAL MEDS^4^178
;;^UTILITY(U,$J,358.4,2323,0)
;;=CYSTOURETHROSCOPY^1^178
;;^UTILITY(U,$J,358.4,2324,0)
;;=PROSTATE BIOPSY & IMAGING^8^178
;;^UTILITY(U,$J,358.4,2325,0)
;;=NURSING PROCEDURES^6^178
;;^UTILITY(U,$J,358.4,2326,0)
;;=MISCELLANEOUS^5^178
;;^UTILITY(U,$J,358.4,2327,0)
;;=IMMUNIZATION ADMIN^2^178
;;^UTILITY(U,$J,358.4,2328,0)
;;=IMMUNIZATIONS^3^178
;;^UTILITY(U,$J,358.4,2329,0)
;;=BLADDER^4^179
;;^UTILITY(U,$J,358.4,2330,0)
;;=BENIGN NEOPLASIA-KIDNEY/URETER^2^179
;;^UTILITY(U,$J,358.4,2331,0)
;;=KIDNEY/URETER^6^179
;;^UTILITY(U,$J,358.4,2332,0)
;;=MALIGNANT NEOPLASMS^7^179
;;^UTILITY(U,$J,358.4,2333,0)
;;=COMPLICATIONS^5^179
;;^UTILITY(U,$J,358.4,2334,0)
;;=NEURO UROLOGY^8^179
;;^UTILITY(U,$J,358.4,2335,0)
;;=BENIGN NEOPLASM-PENIS^3^179
;;^UTILITY(U,$J,358.4,2336,0)
;;=SEXUAL DISORDERS^12^179
;;^UTILITY(U,$J,358.4,2337,0)
;;=PENIS^9^179
;;^UTILITY(U,$J,358.4,2338,0)
;;=POST OPERATIVE COMPLICATIONS^10^179
;;^UTILITY(U,$J,358.4,2339,0)
;;=PROSTATIC CONDITIONS^11^179
;;^UTILITY(U,$J,358.4,2340,0)
;;=TESTICULAR CONDITIONS^14^179
;;^UTILITY(U,$J,358.4,2341,0)
;;=URETHRA^16^179
;;^UTILITY(U,$J,358.4,2342,0)
;;=URINARY SYMPTOMS^16^179
;;^UTILITY(U,$J,358.4,2343,0)
;;=AFTERCARE POST SURGERY^1^179
;;^UTILITY(U,$J,358.4,2344,0)
;;=SUICIDAL IDEATIONS/ATTEMPTS^13^179
;;^UTILITY(U,$J,358.4,2345,0)
;;=PRE-OP VISIT^1^180
;;^UTILITY(U,$J,358.4,2346,0)
;;=CONSULTATION-CLINICIAN^2^180
;;^UTILITY(U,$J,358.4,2347,0)
;;=POST-OP VISIT^3^180
;;^UTILITY(U,$J,358.4,2348,0)
;;=A DIAGNOSIS^1^181
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3BX 3772 printed Oct 16, 2024@18:46:32 Page 2
IBDEI3BX ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.4)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.4,2293,0)
+2 ;;=RETINA - VASCULAR^12^176
+3 ;;^UTILITY(U,$J,358.4,2294,0)
+4 ;;=EYELIDS / LASHES^2^176
+5 ;;^UTILITY(U,$J,358.4,2295,0)
+6 ;;=NEURO / STRABISMUS^18^176
+7 ;;^UTILITY(U,$J,358.4,2296,0)
+8 ;;=ORBIT - PLASTICS^20^176
+9 ;;^UTILITY(U,$J,358.4,2297,0)
+10 ;;=VITREOUS^17^176
+11 ;;^UTILITY(U,$J,358.4,2298,0)
+12 ;;=ORBIT - TRAUMA^19^176
+13 ;;^UTILITY(U,$J,358.4,2299,0)
+14 ;;=LACRIMAL / NLD / NEOPLASMS^3^176
+15 ;;^UTILITY(U,$J,358.4,2300,0)
+16 ;;=MOST FREQUENT^1^176
+17 ;;^UTILITY(U,$J,358.4,2301,0)
+18 ;;=CONJUNCTIVA / SCLERA^4^176
+19 ;;^UTILITY(U,$J,358.4,2302,0)
+20 ;;=CORNEA / ULCER^5^176
+21 ;;^UTILITY(U,$J,358.4,2303,0)
+22 ;;=LENS / CATARACT / POSTOP^6^176
+23 ;;^UTILITY(U,$J,358.4,2304,0)
+24 ;;=IRIS / UVEITIS^7^176
+25 ;;^UTILITY(U,$J,358.4,2305,0)
+26 ;;=GLAUCOMA - OPEN ANGLE^8^176
+27 ;;^UTILITY(U,$J,358.4,2306,0)
+28 ;;=GLAUCOMA - CLOSED ANGLE^9^176
+29 ;;^UTILITY(U,$J,358.4,2307,0)
+30 ;;=GLAUCOMA - SECONDARY^10^176
+31 ;;^UTILITY(U,$J,358.4,2308,0)
+32 ;;=RETINA - CHOROID / TUMORS / INFLAM^14^176
+33 ;;^UTILITY(U,$J,358.4,2309,0)
+34 ;;=RETINA - TEAR / PERIPH / DEGENERATION^15^176
+35 ;;^UTILITY(U,$J,358.4,2310,0)
+36 ;;=RETINA - MACULA^11^176
+37 ;;^UTILITY(U,$J,358.4,2311,0)
+38 ;;=SUICIDE IDEATIONS/ATTEMPTS^23^176
+39 ;;^UTILITY(U,$J,358.4,2312,0)
+40 ;;=PMH / OTHER^22^176
+41 ;;^UTILITY(U,$J,358.4,2313,0)
+42 ;;=RETINA - VEGF INJECT DX CODES^16^176
+43 ;;^UTILITY(U,$J,358.4,2314,0)
+44 ;;=RETINA - DIABETIC RETINOPATHY^13^176
+45 ;;^UTILITY(U,$J,358.4,2315,0)
+46 ;;=NEW PATIENT^2^177
+47 ;;^UTILITY(U,$J,358.4,2316,0)
+48 ;;=ESTABLISHED PATIENT^1^177
+49 ;;^UTILITY(U,$J,358.4,2317,0)
+50 ;;=CONSULTATIONS^3^177
+51 ;;^UTILITY(U,$J,358.4,2318,0)
+52 ;;=POST OP VISIT (GLOBAL)^4^177
+53 ;;^UTILITY(U,$J,358.4,2319,0)
+54 ;;=PENIS & SCROTUM^7^178
+55 ;;^UTILITY(U,$J,358.4,2320,0)
+56 ;;=URINARY TRACT DRAINAGE & IMAGING^9^178
+57 ;;^UTILITY(U,$J,358.4,2321,0)
+58 ;;=URODYNAMICS^10^178
+59 ;;^UTILITY(U,$J,358.4,2322,0)
+60 ;;=INJ & INTRAVESICAL MEDS^4^178
+61 ;;^UTILITY(U,$J,358.4,2323,0)
+62 ;;=CYSTOURETHROSCOPY^1^178
+63 ;;^UTILITY(U,$J,358.4,2324,0)
+64 ;;=PROSTATE BIOPSY & IMAGING^8^178
+65 ;;^UTILITY(U,$J,358.4,2325,0)
+66 ;;=NURSING PROCEDURES^6^178
+67 ;;^UTILITY(U,$J,358.4,2326,0)
+68 ;;=MISCELLANEOUS^5^178
+69 ;;^UTILITY(U,$J,358.4,2327,0)
+70 ;;=IMMUNIZATION ADMIN^2^178
+71 ;;^UTILITY(U,$J,358.4,2328,0)
+72 ;;=IMMUNIZATIONS^3^178
+73 ;;^UTILITY(U,$J,358.4,2329,0)
+74 ;;=BLADDER^4^179
+75 ;;^UTILITY(U,$J,358.4,2330,0)
+76 ;;=BENIGN NEOPLASIA-KIDNEY/URETER^2^179
+77 ;;^UTILITY(U,$J,358.4,2331,0)
+78 ;;=KIDNEY/URETER^6^179
+79 ;;^UTILITY(U,$J,358.4,2332,0)
+80 ;;=MALIGNANT NEOPLASMS^7^179
+81 ;;^UTILITY(U,$J,358.4,2333,0)
+82 ;;=COMPLICATIONS^5^179
+83 ;;^UTILITY(U,$J,358.4,2334,0)
+84 ;;=NEURO UROLOGY^8^179
+85 ;;^UTILITY(U,$J,358.4,2335,0)
+86 ;;=BENIGN NEOPLASM-PENIS^3^179
+87 ;;^UTILITY(U,$J,358.4,2336,0)
+88 ;;=SEXUAL DISORDERS^12^179
+89 ;;^UTILITY(U,$J,358.4,2337,0)
+90 ;;=PENIS^9^179
+91 ;;^UTILITY(U,$J,358.4,2338,0)
+92 ;;=POST OPERATIVE COMPLICATIONS^10^179
+93 ;;^UTILITY(U,$J,358.4,2339,0)
+94 ;;=PROSTATIC CONDITIONS^11^179
+95 ;;^UTILITY(U,$J,358.4,2340,0)
+96 ;;=TESTICULAR CONDITIONS^14^179
+97 ;;^UTILITY(U,$J,358.4,2341,0)
+98 ;;=URETHRA^16^179
+99 ;;^UTILITY(U,$J,358.4,2342,0)
+100 ;;=URINARY SYMPTOMS^16^179
+101 ;;^UTILITY(U,$J,358.4,2343,0)
+102 ;;=AFTERCARE POST SURGERY^1^179
+103 ;;^UTILITY(U,$J,358.4,2344,0)
+104 ;;=SUICIDAL IDEATIONS/ATTEMPTS^13^179
+105 ;;^UTILITY(U,$J,358.4,2345,0)
+106 ;;=PRE-OP VISIT^1^180
+107 ;;^UTILITY(U,$J,358.4,2346,0)
+108 ;;=CONSULTATION-CLINICIAN^2^180
+109 ;;^UTILITY(U,$J,358.4,2347,0)
+110 ;;=POST-OP VISIT^3^180
+111 ;;^UTILITY(U,$J,358.4,2348,0)
+112 ;;=A DIAGNOSIS^1^181
